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INTRODUCTION 
COPD is the fourth common cause of death worldwide killing more than 
3 million people annually
1
. It is estimated to become the third common cause of 
death by 2030. COPD is estimated to cause half a million deaths annually in 
india
2
. 
 
The prevalence of COPD in India is estimated to be 3.49% based on 
nationwide prevalence study conducted by ICMR
3
. But since these prevalence 
studies were conducted based on respiratory symptoms questionnaire and 
spirometry was not done to define irreversible airway obstruction it is estimated 
that the actual prevalence and disease burden may be higher. Apart from the 
mortality, COPD causes loss of productivity, huge increases in health 
expenditure and decreased quality of life. 
  
COPD is commonly associated with other chronic diseases because of the 
common risk factors involved like cigarette smoking and obesity. These 
associated disease conditions might contribute significantly to the symptoms 
and severity in the affected patients. The diseases associated with COPD 
include congestive heart failure, arrhythmias, peripheral artery disease, coronary 
artery disease, diabetes, hypertension, osteoporosis, cachexia, chronic renal 
failure, infections and lung cancer. It is important to screen COPD patients for 
the associated comorbid illness since addressing these associated illness can 
lead to better patient management. 
 
The prevalence of chronic renal failure increases with age. Chronic renal 
failure is associated with many chronic diseases such as diabetes, hypertension, 
and congestive heart failure. The association of chronic renal failure with COPD 
has been recognized only recently. This might have therapeutic implications 
like modification of dose of drugs excreted by kidneys. Understanding the 
pathogenesis of renal failure in COPD can lead to novel treatment strategies in 
the management of COPD in future. 
 
The association of chronic renal failure with COPD has been 
demonstrated in western population. This association has not been studied in 
our patients. Hence we took up the study to find the association of renal failure 
in COPD patients and its significance. 
  
 
REVIEW OF LITERATURE 
 
 
Chronic obstructive pulmonary disease (COPD) is a preventable disease 
characterized by expiratory airflow limitation which is usually progressive .The 
disease is due to an abnormal inflammatory response of the lung to noxious 
particles or gases, in almost all patients due to cigarette smoking. In many 
patients it could be due to exposure to pollutants and noxious gases due to 
cooking with biomass fuels especially in developing countries and this could 
explain disease in nonsmokers
4
. Chronic bronchitis and emphysema are two 
conditions found commonly associated with COPD. 
 
 
 
 
 
 
 
 
EMPHYSEMA: 
Emphysema can be defined pathologically as the enlargement of distal airways 
due to destruction of acinus and disappearance of alveolar septae. This results in 
characteristic loss of elastic recoil which in turn causes slowing of airflow from 
the lungs, hyperinflation, and air-trapping. 
 FIGURE 1: PATHOGENESIS OF EMPHYSEMA 
 
CHRONIC BRONCHITIS 
Chronic bronchitis is characterized by chronic cough and sputum 
production, which is present in about one out of three people with early COPD. 
It is defined as productive cough on most days of the month for at least 3 
consecutive months per year for at least 2 consecutive years. 
 
  Chronic cough and sputum production in cigarette smokers may not be 
associated with chronic airflow obstruction. Chronic obstructive bronchitis 
defines chronic mucus hypersecretion associated with airflow obstruction. The 
anatomic correlates of chronic bronchitis are mucus gland hyperplasia and 
goblet cell metaplasia in large and medium-size airways. Patients with COPD 
can also have inflammation, narrowing, tortuosity and fibrosis of the small and 
medium-size airway that contributes to the airflow limitation. 
 
Some long-standing asthmatics develop airflow obstruction that is not 
completely reversible, episodes of cough and wheeze, and chronic sputum 
production. These individuals are said to have chronic asthmatic bronchitis and 
tend to have a somewhat better prognosis for survival than those with typical 
COPD associated with cigarette smoking. It is difficult to distinguish between 
these two subgroup of patients. 
DIAGNOSIS: 
Physical examination and chest imaging are insensitive methods for 
diagnosis of COPD. Physical findings of hyperinflated lungs such as low-lying 
diaphragms, decreased breath sounds and hyperresonant chest percussion are 
highly specific for COPD, but usually only in advanced disease. It has been 
suggested in a study that a distance between the thyroid cartilage and the sternal 
notch less than 4 cm in a smoker older than age 45 is highly indicative of the 
presence of COPD. Clubbing of the fingers is not common in COPD and, if 
present, suggests another diagnosis such as bronchiectasis, asbestosis, or lung 
cancer. 
 
  High-resolution computed tomography (HRCT) of the lung, analyzed by 
quantitative measures of lung density, is a promising technique for early 
detection of emphysema, but the role of HRCT in early detection and 
monitoring of COPD is not established at present. 
α1-Antitrypsin deficiency is an uncommon, but not rare, condition 
associated with premature emphysema. Testing for α1-antitrypsin deficiency is 
indicated in patients with premature disease. 
  HIV/AIDS is also associated with premature emphysema, and screening 
for HIV should be considered in persons with emphysema and HIV risk factors 
such as intravenous drug use or high-risk sexual activity. 
 
SPIROMETRY 
The spirometry is a simple, noninvasive, and inexpensive test used in the 
diagnosis of COPD. Spirometry is also used in the classification of its severity 
and monitoring the progression of the disease. The FEV1/FVC ratio reflecting 
the rate of emptying of the lung is used to define the presence of an obstructive 
ventilatory defect. A ratio less than 0.70 is used to define COPD. Once airflow 
obstruction is established, the severity of the disease is classified by the 
reduction of FEV1 compared with a healthy reference population. 
 Table 42-2 
 
 
 
STAGE  CHARACTERISTICS 
I MILD COPD FEV1 80% predicted 
II 
MODERATE 
COPD 
FEV1 50%–79% predicted 
 
III SEVERE COPD FEV1 30% to 49% predicted 
IV 
VERY SEVERE 
COPD 
FEV1 <30% predicted or <50%predicted 
with room air  PaO2 <60 mm Hg (8.0 kPa) 
 
TABLE 1: CLASSIFICATION OF COPD SEVERITY
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CONDITIONS SUGGESTING ALPHA 1 ANTI- TRYPSIN 
DEFICIENCY
6
 
1. Early-onset emphysema (age under 45 years). 
2. Emphysema in a nonsmoker. 
3. Emphysema predominantly in lung bases (pan-acinar). 
4. Necrotizing panniculitis (Weber-Christian disease). 
5. C-ANCA positive vasculitis (e.g.,Wegener’s granulomatosis). 
6. Family history of early onset emphysema or non-smoking–related 
emphysema. 
7. Bronchiectasis without other etiology. 
 PROGNOSIS 
The median survival after the diagnosis of COPD is 10 years. But the 
disease has one of widely varying rates of progression. Death is often due to 
susceptibility to intercurrent illness and other smoking related illness such as 
lung cancer rather than progressive respiratory failure. 
 
The  factors that have been identified to predict poor survival in COPD 
include low FEV1, active smoking status, hypoxemia, poor nutrition, the 
presence of cor pulmonale, resting tachycardia, low exercise capacity, severe 
dyspnea, poor health-related quality of life, anemia, frequent exacerbations, co-
morbid illnesses, and low carbon monoxide diffusing capacity. 
 
Patients with an FEV1 less than 35 percent predicted have about 10 percent 
mortality per year. If a patient reports that they are unable to walk 100 meters 
without stopping because of breathlessness, the 5-year survival is only 30 
percent. 
 
 
 
BODE INDEX 
7
 
  A multidimensional prognostic index that takes into account several 
indicators of COPD prognosis is the BODE index (body mass index [BMI], 
obstructive ventilator defect severity, dyspnea severity, and exercise capacity).  
The components are derived from  
1. Body mass index (weight in kg/ square of height in m). 
2. FEV1 percent predicted. 
3. Modified Medical Research Council (MMRC) dyspnea score. 
4. Distance walked in 6 minutes in meters. 
 
  A BODE score greater than 7 is associated with a 30 percent 2-year 
mortality; whereas a score of 5 to 6 is associated with 15 percent 2-year 
mortality. If the BODE score is less than 5, the 2-year mortality is less than 10 
percent. 
 
 
 
 
VARIABLE 0 1 2 3 
FEV1 (% predicted) ≥65 50 – 64 36 – 49 ≤35 
Distance walked in 6 min (meters) ≥350 250 – 349 150 – 249 ≤149 
MMRC dyspnea scale 0 – 1 2 3 4 
Body-mass index (kg/M2) <21 ≥21   
 
TABLE 2: CALCULATION OF BODE INDEX 
 
     
GRADE DESCRIPTION 
0 Not troubled with breathlessness except with strenuous exercise. 
1 
Troubled by shortness of breath when hurrying on the level or 
walking up a slight hill 
2 
Walks slower than people of the same age on the level because of     
breathlessness or has to stop   for breath when walking at own 
pace on the level.  
3 
Stops for breath after walking about 100 yards or after a few 
minutes on the level. 
4 
Too breathless to leave the house or breathless when dressing or 
undressing. 
TABLE 3: MODIFIED MEDICAL RESEARCH COUNCIL DYSPNOEA 
(MMRC) 
8 
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MANAGEMENT OF COPD 
SMOKING CESSATION 
 In patients who continue to smoke cigarettes there are no proven 
treatments that prevent the progression of COPD. Cessation of smoking halts the 
excessive decline in lung function. Hence efforts directed to stop smoking 
should be a primary goal for physicians caring for COPD patients. Patients with 
mild or moderate COPD who are asymptomatic might be unaware of the fact 
that they have underlying lung disease that can be halted by smoking cessation 
or may adopt a fatalistic attitude that it is too late for help. 
 
Even patients with severe disease who are dyspneic at rest or use 
continuous oxygen may continue to smoke cigarettes or relapse after quitting. 
At each patient encounter smoking history should be obtained because many 
patients do not volunteer the extent of their smoking or report a smoking relapse 
following cessation. In patients who do smoke, achieving cessation should be a 
primary and persistent goal of treatment. 
 
  The counseling by the physician should emphasize the harm of continued 
smoking, the benefits of cessation in terms of activities that are meaningful for 
the individual and the understanding that smoking cessation is a realistic and 
achievable goal. It has been proven in several studies that counseling by the 
physician has shown to improve quitting rates. Other measures useful in helping 
the patient to quit smoking are assistance with pharmacologic adjuncts such as 
nicotine replacement therapy, varenicline or bupropion and referral to smoking 
cessation groups. 
 
  Follow-up of smoking status and repeated smoking cessation messages 
should be performed at each encounter. Smoking cessation messages can be 
reinforced through telephonic messages or even letters. The key to successful 
smoking cessation is the understanding on the part of physician that inability to 
quit or relapse after quitting is due to strong physical addiction and does not 
imply the lack of will or moral weakness on the patient’s part.  
 
 
Hence smoking cessation efforts require perseverance of the patient as 
well as the physician in pursuing this ideal goal to halt the disease progression. 
Exposure to respiratory irritants should be avoided in COPD patients as this can 
accelerate the decline in lung function. 
 
NICOTINE REPLACEMENT THERAPIES 
A wide variety of nicotine replacement formulations have been 
developed. These include tablets, polacrilex (gum), transdermal systems, nasal 
spray, a variety of inhalers, and nicotine toothpicks. Five formulations are 
currently approved as aids for smoking cessation in the United States, and three 
are available over the counter. All have demonstrated about twofold increases in 
quit rates above placebo in clinical trials. 
 
PHARMACOLOGIC THERAPY 
BUPROPION 
Bupropion, an antidepressant, has been demonstrated to be an effective 
aid in smoking cessation. In clinical trials, bupropion has doubled the quit rates 
compared with placebo.  It acts by potentiating dopaminergic and noradrenergic 
signaling.  
 
Patients with a history of depression, but did not benefit from nicotine 
replacement appeared to benefit from bupropion. Bupropion may be a superior 
initial choice in such individuals. Combination of nicotine replacement with 
bupropion has been proven to be more effective than either agent alone.   
 
The currently recommended dose is 150 mg daily for 3 days followed by 
150 mg twice daily. The quit date should be after a week of therapy so that 
blood levels are established. 
 
The drug is generally well tolerated. Side effects are dry mouth and 
insomnia. In combination with nicotine replacement an increase in blood 
pressure may also occur. A reduction in seizure threshold occurs. Hence the 
drug is contraindicated among those predisposed to seizures, or with anorexia 
nervosa or bulimia.  
   
 
The appropriate duration of therapy is not established. Clinical trials that 
formed the basis for approval treated for 7 weeks. However, with prolonged 
therapy, there is an increase in secondary quits, and therapy for 1 year, resulted 
in more quits than therapy for 7 weeks. 
 
OFF-LABEL AGENTS 
CLONIDINE 
Clonidine is an α-adrenergic agonist, centrally acting antihypertensive. A 
number of clinical trials have evaluated its efficacy in smoking cessation and is 
proven to be effective. 
 
NORTRIPTYLINE 
Nortriptyline is a tricyclic antidepressant that has been evaluated for 
efficacy in smoking cessation in several studies. Both individual studies and a 
meta-analysis support its benefit as an aid to smoking cessation, and it is also 
recommended as a possible second-line agent. 
 
A number of other agents approved for other uses have also been assessed 
for smoking cessation. None are currently recommended off-label by 
established guidelines.  
These include 
1. Topiramate, an antiepileptic that has shown promise for combined 
alcohol and tobacco addiction. 
2. Selegiline, an agent used in the treatment of Parkinson’s disease that has 
also shown promise in smoking cessation. 
3. Several other agents, including selective serotonin reuptake inhibitors 
(SSRIs) antidepressants, opiate antagonists, anxiolytics and 
amphetamines have been demonstrated to be without benefit. 
 
Several drugs are under active investigation for smoking cessation. 
Varenicline is a nicotine receptor partial agonist that has looked promising in 
phase 2 and 3 clinical trials. As a partial agonist, it has the potential to mitigate 
some of the nicotine withdrawal syndrome. Also, as a partial agonist, it may 
function as an inhibitor and block some nicotine effects, and thus may prevent 
full relapse. 
 
Rimonobant is a CB1 receptor antagonist. It appears to attenuate a wide 
variety of cravings and has shown promise in clinical trials for smoking and for 
obesity. 
 
VACCINATION 
Although the evidence of its particular efficacy in COPD is lacking 
Pneumococcal vaccination is recommended. Annual influenza immunization 
can prevent or attenuate this potentially fatal infection. The killed vaccine is 
preferred, as cold attenuated live influenza vaccines have not been approved for 
use in older patients and those with underlying lung disease. 
 
For individuals who are not immunized, prophylaxis with amantadine or 
rimantadine during an influenza epidemic can often prevent infection with 
influenza A. Due to the emergence of resistant strains and side effects these 
drugs have limited usefulness. During influenza epidemics, the use of 
neuraminidase inhibitors such as zanamivir and oseltamivir can minimize 
severity of infection if taken within 48 hours of onset of illness and are useful 
against both influenza A and B, and may limit the spread of infection. 
 
ALPHA 1 ANTI TRYPSIN REPLACEMENT 
It is indicated in individuals with severe deficiency. Studies have 
demonstrated that individuals with moderate degrees of impairment (FEV1 35 
to 65 percent predicted) appear to benefit most in terms of preservation of lung 
function and improved survival. The human plasma-derived preparation of α1-
antitrypsin is administered intravenously in a dose of 60 mg/kg weekly. 
 
EXERCISE AND REHABILITATION 
Regular prudent self-directed exercise is recommended for all individuals 
with COPD. This helps to prevent the muscle deconditioning that often 
accompanies the disorder. Individuals should be encouraged to perform at least 
20 to 30 minutes of constant low-intensity aerobic exercise such as walking at 
least three times per week. Even the most severely impaired patients with 
COPD can usually attain an exercise regimen of 30 minutes of walking at 1 mph 
(i.e., one-half mile in 30 minutes). It is important to instruct patients that they 
should exercise to a level of dyspnea that is tolerable for the entire exercise 
period. 
 
NUTRITION SUPPORT 
About 50 % of patients with very severe COPD (FEV1 less than 35 
percent of predicted value) show protein-calorie malnutrition. The possible 
mechanisms include increased resting metabolic demands, inadequate caloric 
intake due to dyspnea and anorexia, and production of cachexia-associated 
inflammatory cytokines such as TNF-α, IL-1, and IL-6. 
 
  Patients with a BMI of less than 90 percent of normal have increased 
mortality and decreased exercise capacity. Muscle wasting and loss of bone 
mass may be present even in patients who have normal BMI. 
 
It is prudent to monitor body weight in COPD patients and encourage 
caloric supplementation as needed since those patients who do gain weight 
show improved survival. But clinical trials of nutritional supplementation have 
not been proven effective. 
High-fat diets have the theoretical advantage of offering higher caloric 
content with lower CO2 production than high carbohydrate diets, but there is no 
convincing evidence that this strategy is clinically superior to a well-balanced 
diet. For patients with less advanced disease, a balanced diet with avoidance of 
overweight or underweight is a rational goal. 
 
SLEEP DISORDERS IN COPD 
Sleep disturbances are often overlooked in COPD. These are common 
symptoms in patients with COPD, including insomnia and daytime 
hypersomnolence. The causes for sleep symptoms are multifactorial and include 
anxiety/panic disorder due to fear of suffocation while sleeping, depression, 
resting hypoxemia, nocturnal bronchospasm, sleep apnea, associated diseases 
such as obstructive sleep apnoea and gastro esophageal reflux disease and 
nocturnal oxygen desaturation. In patients with COPD and sleep disturbances 
these causes should be sought and treated accordingly to improve the quality of 
life. 
 
 
 
 
 
 
LONG TERM OXYGEN THERAPY 
Apart from smoking intervention in early COPD, treatment of resting 
daytime hypoxemia with oxygen is a treatment that prolongs survival.  
The two strongest indications for prescription of long-term oxygen therapy are: 
1. Resting room-air PaO2 ≤ 55 mmHg or oxygen saturation ≤ 88 percent 
while a person is in usual state of health; and 
2.  Resting room-air PaO2 56 to 60 mmHg or oxygen saturation 88 to 89 
percent with supporting evidence of chronic hypoxemia such as 
polycythemia, pulmonary hypertension, cor pulmonale, or psychological 
impairment. 
  
Oxygen is usually administered by nasal cannula, with the flow rate adjusted 
to maintain a resting saturation greater than 90 percent. The usual starting flow 
rate is 2 L/min, although some patients with severe hypercapnia require lower 
flows. 
 
 
The most convenient and cost-effective oxygen source at home is usually a 
concentrator device that uses a molecular sieve to extract oxygen from room air. 
For ambulation, small compressed air cylinders or liquid oxygen reservoirs that 
can be carried provide patients with the ability to leave their homes. Ideally, 
oxygen should be used constantly 24 hours per day or at least 18 hours of 
oxygen per day, however, substantial improvement has been demonstrated with 
use over 12 hours per day. If continuous oxygen supplementation is prescribed 
following an exacerbation of COPD, it is recommended to check arterial oxygen 
levels in 6months, as many patients will no longer require oxygen.  
Smoking or exposure to any open flame, of course, is dangerous and 
prohibited in those who use oxygen. 
Transtracheal oxygen administered via a percutaneous catheter is useful for 
patients who need high oxygen concentrations or in whom use of a nasal 
cannula is not tolerated because of local nasal adverse effects or cosmetic 
preference. Transtracheal oxygen has the advantage of decreasing effective dead 
space ventilation and permitting lower flow rates to provide high oxygen 
concentrations. Complications include local infection, pneumothorax and 
pneumomediastinum. 
TREATMENT OF ANEMIA 
Anemia present in about 10 percent of patients with severe COPD, 
similar to other chronic inflammatory diseases, and is a poor prognostic 
indicator. Patients with COPD have a lower erythropoietic response to hypoxia 
than healthy people at altitude. For patients who are anemic and breathless, 
restoration of normal hemoglobin content reduces resting minute ventilation and 
work of breathing, which presumably improves exercise capacity. 
 
DRUG THERAPY 
Bronchodilators and anti-inflammatory agents are used in COPD to 
reverse bronchoconstriction and improve airflow limitation. The goals of drug 
therapy are not only to improve lung function, but also to improve quality of 
life, exercise capacity, and prevent exacerbations. No drug treatment is known 
to diminish the decline in pulmonary function with continued smoking, or 
substantially reduce mortality. 
 
 
Inhaled bronchodilators are the cornerstone in the symptomatic 
management of COPD. They are given on a regular basis to maintain 
bronchodilation and as and when needed to relieve symptoms. Both beta-
agonist and anticholinergic classes are available in short duration (4- to 6-hour) 
and long-duration (12- to 24-hour) forms. The choice of bronchodilator class 
and duration of effect depends upon the preference of the patient and the cost. 
 
  Combination of different classes of bronchodilators is often more 
effective than increasing the dose of a single agent, and combination inhalers 
can simplify treatment regimens. Patients with advanced COPD often use a 
combination of bronchodilators, including long acting maintenance 
anticholinergics and beta agonists as well as symptomatic use of shorter-acting 
bronchodilators. Individuals with frequent exacerbations often benefit from a 
combination inhaler of corticosteroids and long-acting bronchodilator. 
 Long-acting oral preparations of theophylline are useful adjuncts in cases 
in which inhaled medication is too expensive or not acceptable for the patient. 
  Chronic use of systemic corticosteroids should be reserved for individuals 
with very frequent or life-threatening exacerbations who cannot tolerate their 
discontinuation. Response to treatment is judged by symptomatic improvement 
and functional status. Patients on long-term systemic steroids should receive 
prophylaxis for osteoporosis with calcium and vitamin D or bisphosphonates 
and should be instructed about the need for stress-dose steroids for acute 
illnesses.  
 
Inhaled corticosteroids are most useful in patients who have an overlap 
with asthma and in advanced disease who have frequent exacerbations. Inhaled 
corticosteroids can reduce the frequency of exacerbations, improve airways 
reactivity, and quality of life. Inhaled corticosteroids, although poorly absorbed, 
probably do contribute to steroid side effects such as cataracts, capillary 
fragility, and osteoporosis in susceptible individuals. Hence it is prudent to 
prescribe the lowest effective dose. In patients who are at risk for osteoporosis 
(i.e., older age, cigarette smoking, and low exercise) as most patients with 
COPD are, it is prudent to recommend prophylactic treatment such as calcium 
supplements and vitamin D. In those with established osteoporosis, 
bisphosphonates are advised. 
 COMPLICATIONS OF COPD 
1. Acute exacerbation of COPD 
2. Pneumothorax. 
3. Hypercapnia. 
4. Cor pulmonale. 
5. Supraventricular arrhythmias. 
6. Respiratory failure. 
 
  
FIGURE 2: STEPWISE ALGORITHM FOR MANAGEMENT OF COPD 
Indications for Hospital Assessment or Admission for COPD 
Exacerbation
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 Sudden onset of new or severe symptoms (e.g., dyspnea). 
Figure 1STEPWISE  ALGORITHM FOR THE 
MANAGEMENT OF COPD 
 Inability to sleep or eat because of dyspnea. 
 Severe or very severe underlying COPD. 
 Onset of new physical findings (e.g., edema, cyanosis, change in mental 
status). 
 Failure to respond to initial medical treatment. 
 Associated comorbidities (e.g., cardiac, renal, hepatic failure, or diabetes). 
 Diagnostic uncertainty (e.g., suspected pneumonia or pulmonary embolism). 
 Unusual presenting symptoms. 
 Older age or frailty. 
 Inadequate home or social support. 
 History of poor adherence with treatment. 
 
 
 
Indications for ICU Admission for COPD Exacerbation 
 Severe dyspnea unresponsive to initial treatment. 
 Change in mental status (e.g., confusion, lethargy, coma). 
 Persistent or worsening hypoxemia, hypercapnia, or respiratory acidosis. 
 Need for sedation or narcotic pain control.  
GLOMERULAR FILTRATION AS A MARKER OF   RENAL 
FUNCTION: 
Glomerular filtration rate (GFR) is considered to be the optimal test for 
the assessment of renal function. It is the volume of fluid filtered from the renal 
glomerular capillaries into the Bowman’s space per unit time. It is the product 
of average filtration rate of nephron multiplied by the total number of nephrons 
in both kidneys
11
. 
The normal GFR varies according to age, sex, body size, physical 
activity, diet, pregnancy, drug intake etc.
12
.The normal GFR is 130 ml/min/1.73 
sq. m body surface area in males. The normal GFR in females is 120 
ml/min/1.73 sq. m. GFR is 8% higher in young men than women. GFR also 
falls by 10% during midnight. GFR increases by 50% during the first trimester 
of pregnancy but becomes normal after delivery. GFR decreases with increasing 
age. It falls by approximately 0.75 ml/min /year after 40 years of age. An 
important pitfall in using the GFR for estimating renal function is that GFR 
might remain normal despite substantial reduction in renal function. 
 
GFR cannot be measured directly. It is measured as the urinary clearance 
of a chemical either endogenous or exogenous. The ideal chemical should have 
a steady level in the plasma, should be freely filtered but neither reabsorbed nor 
secreted by the renal tubules.  
GFR is calculated as follows 
GFR = (urine concentration x urine flow)/plasma concentration. 
Creatinine is the most commonly used endogenous filtration marker in 
the estimation of GFR by calculating creatinine clearance. Creatinine is 
produced by the breakdown of creatine phosphate in muscle. Other sources are 
intake of meat in diet or creatine supplements. It is freely filtered by the 
glomeruli but actively secreted by tubules. Drugs inhibiting tubular secretion of 
creatinine can increase the serum creatinine levels. Patients with decreased 
muscle mass can have low serum creatinine levels. 
Creatinine clearance (C Cr) is calculated from the concentration of 
creatinine in a collected sample of urine (U Cr), urine flow rate (V), and plasma 
creatinine concentration (P Cr). 
C Cr = (U Cr x V)/P Cr. 
Creatinine clearance is not measured routinely to estimate GFR due to 
difficulty in measuring creatinine concentration in 24 hour urine sample. 
 
As an alternative to the cumbersome procedure of measuring creatinine 
clearance directly several methods of estimating creatinine clearance were 
devised such as 
1. Cockroft – Gault formula. 
2. MDRD (modification of diet in renal disease) formula. 
3. CKD EPI (chronic kidney disease epidemiology collaboration) formula. 
 
 
 
 
 
 
 
HYPONATREMIA 
The normal serum sodium ranges from 135 -145 mEq/L. Hyponatremia is 
defined is serum sodium < 135 mEq/L. Sodium is the principal extracellular 
cation which determines the extracellular fluid osmolarity. Sodium plays an 
important role in regulating the osmolarity of extracellular fluid and effective 
circulating blood volume. The movement of sodium across cell membrane is an 
energy dependent process and requires Na-K ATPase pump. 
Normal diet provides 4-7 g of sodium per day. One teaspoon of table salt 
has 6 g NaCl of which sodium constitutes 2.4 g. 1 g of sodium is equivalent to 
43 mEq of sodium. 1 g of NaCl yields 17 mEq of sodium. 
In the kidneys 60% of filtered sodium is reabsorbed in the proximal 
tubule by      Na
+
 H
+
 exchange. In the thick ascending limb of Henle’s loop 30% 
of filtered sodium is reabsorbed via the Na
+
 K
+
 2Cl
-
 cotransporter. 7% is 
reabsorbed in the distal convoluted tubule through the Na
+
 Cl
-
 cotransporter. 
The remaining 3% of filtered sodium reaches the collecting duct. Sodium 
absorption in this portion of nephron takes place through epithelial sodium 
channels regulated by aldosterone. Sodium is actively reabsorbed in all the 
segments of nephron except the thin portions of the loop of Henle. 
The kidneys reabsorb 96 – 99% of the filtered sodium. The urine sodium 
excretion varies from <1 mEq to >400 mEq/ day depending on the sodium 
content in diet. The changes in the renal excretion of sodium is brought by 
changes in GFR and changes in the tubular sodium reabsorption especially in 
the 3% of the filtered sodium that reaches the collecting ducts
13
. 
The factors regulating sodium reabsorption are 
1. The circulating aldosterone levels. 
2. Other adrenocortical hormones. 
3. Circulating ANP levels. 
4. Rate of tubular secretion of potassium and hydrogen ions. 
 
 
 
 
Hyponatremia can be classified into different types 
11
. 
1. Translocational hyponatremia. 
2. Pseudohyponatremia. 
3. Hypovolemic hyponatremia. 
4. Euvolemic hyponatremia. 
5. Hypervolemic hyponatremia. 
 
TRANSLOCATIONAL HYPONATREMIA 
Osmotically active substances in the extracellular fluid can draw water 
from inside the cell into the extracellular compartment leading to an apparent 
hyponatremia. For example in hyperglycemic states such as diabetic 
ketoacidosis every 100 mg/dl rise in plasma glucose level above the normal 
value of 100 mg/dl can decrease the plasma sodium by 1.6 m mol/L. Other 
osmotically active substances such as mannitol, glycine can also lead to this 
type of hyponatremia. 
 
 
 
PSEUDOHYPONATREMIA 
In hypertryglyceridemias and paraproteinemias the solid phase of plasma 
is greatly increased. This can lead to apparently low serum sodium levels. This 
is prevented by measuring serum sodium by direct and indirect ion sensitive 
potentiometry. 
 
HYPOVOLEMIC HYPONATREMIA 
This can be caused by renal or extrarenal fluid loss such as excessive 
diuretics, mineralocorticoid deficiency, salt losing nephropathy, diarrhoea, 
vomiting etc. The hypovolemia causes stimulation of thirst and non-osmotic 
release of ADH. Water retention occurs and resuts in hyponatremia. 
 
 
  
EUVOLEMIC HYPONATREMIA 
In this condition the total body water is increased but there is no change 
in the total body sodium. Causes include hypothyroidism, glucocorticoid 
deficiency, and drugs like clofibrate, haloperidol, amitryptiline, NSAIDS, 
sertraline and SIADH. 
 
 
HYPERVOLEMIC HYPONATREMIA 
In this condition both the total body water and sodium are increased, the 
increase in total body water is more than the increase in total body sodium. It is 
caused by nephrotic syndrome, cirrhosis and congestive cardiac failure.in these 
disease states the underfilling of the arterial circulation causes stimulation of the 
renin angiotensin aldosterone system leading to the retention of salt and water. 
Stimulation of the ADH release causes water retention. The severity of 
hyponatremia in these conditions is a prognostic marker of the underlying 
disease.  
 
CLINICAL FEATURES OF HYPONATREMIA 
At serum sodium levels >125 the patients are usually asymptomatic. At 
levels  less than 125 patients can have symptoms such as headache, lethargy, 
nausea, seizures and coma, respiratory depression and death due to increase in 
intracranial pressure.  
The increase in intracranial pressure is due to osmotic shift of water into 
the neurons as a result of hypo osmolarity of the extracellular fluid. Elderly 
patients are usually asymptomatic even at serum sodium levels<120 mEq/L. 
This is due to cerebral atrophy and the increased space available within the 
cranium for the brain to expand. Children are particularly susceptible to the 
effects of hyponatremia due to the high ratio of brain to skull volume. 
CENTRAL PONTINE MYELINOLYSIS 
Rapid correction of hyponatremia is suicidal and can result in osmotic 
demyelination syndrome. This rapid correction of serum sodium levels can 
cause movement of water from within the cells to the ECF. This rapid shrinkage 
when it occurs in the neurons can lead on to osmotic demyelination syndrome 
or central pontine myelinolysis. 
The more severe form of the disease is characterized by flaccid paralysis, 
dysarthria and dysphagia. Diagnosis can be confirmed by CT or MRI brain. 
Risk of this catastrophic complication is increased in chronic hyponatremia >48 
hrs duration, pre-existing hypokalemia, malnutrition, alcoholism and children. 
To prevent this complication, correction of hyponatremia should be 
gradual and guided by frequent monitoring of the patients clinical condition and 
serum sodium levels. If the patient is acutely symptomatic such as in coma or 
seizures hyponatremia can be corrected at the rate of 1-2 mEq/L for 3-4 hrs. 
Once the patient’s clinical condition improves the rate of correction should be 
more gradual such that rate of increase in serum sodium should not exceed 10-
12 mEq/L in a 24 hr period. In chronic hyponatremia the correction should not 
exceed 6-8 mEq/L in a 24 hr period. 
 
 
 
 
 
RENAL FAILURE AND HYPONATREMIA IN COPD 
Edema and hyponatremia are found in a large proportion of patients with 
COPD. The cause of edema in COPD was thought to be cor pulmonale ie the 
hypoxia induced by COPD causes pulmonary hypertension, right ventricular 
hypertrophy and eventually right heart failure. Later it was found that edema in 
COPD could not be attributed to cor pulmonale as cardiac output was found to 
be adequate for the body’s metabolic demands in most such patients unless they 
had significant underlying cardiac disease
14,15
. 
 
In 1960, Campbell and Short observed that edema in COPD patients is 
invariably associated with carbon-di-oxide retention
16
. This observation has lead 
to a change in our understanding of the pathogenesis of edema in COPD. 
Hypercapnia causes local adrenergic discharge which results in renal 
vasoconstriction and reduced renal plasma flow but the glomerular filtration rate 
is preserved until the late stages of the disease. The normal glomerular filtration 
despite the reduced renal plasma flow increases the filtration fraction and 
peritubular oncotic pressure. This leads to sodium and water retention
17 
 
  Other mechanisms such as enhanced renal tubular sodium reabsorption 
through Na
+
-H
+
 exchange in response to hypercapnia and respiratory acidosis 
and imbalance in hormones that regulate sodium and water imbalance are also 
implicated
18
. PaCO2 has been found to inversely correlate with renal plasma 
flow and sodium and water excretion. 
 TABLE 4: CHANGES IN THE RENAL HEMODYNAMICS AND 
HORMONES REGULATING SODIUM AND WATER BALANCE IN 
PATIENTS WITH MILD TO MODERATE COPD AND SEVERE COPD 
 
Table 4 depicts the changes in renal plasma flow, glomerular filtration and 
changes in various hormones that regulate sodium and water balance in patients 
with mild to moderate and severe COPD .These changes are triggered by carbon 
dioxide retention. 
 
  
FIGURE 3: PATHOGENESIS OF EDEMA AND HYPONATREMIA IN 
COPD PATIENTS 
 
 
 
 
 
HORMONAL ABNORMALITIES IN COPD  
During the early stages of COPD the carbon-di-oxide retention causes an 
increase in the renal sympathetic tone and sodium retention
19, 20, 21
. Early in the 
disease course the carbon-di-oxide retention causes decrease in the renal plasma 
flow without compromising the GFR. As the disease progresses when the GFR 
starts to fall the renin angiotensin aldosterone system is activated which results 
in sodium and water retention 
22, 23, 24
. 
 
  Another proposed mechanism for sodium and water retention leading to 
edema is as follows. Hypercapnia in COPD induces dilatation of the 
precapillary sphincters causing under filling of the arterial system. This 
stimulates the renin angiotensin aldosterone system. The resulting sodium and 
water retention is unable to fill the dilated arterial system creating a vicious 
cycle of sodium retention and massive edema. 
 
 
 
In a number of edematous patients with COPD significant hyponatremia 
is present. Plasma antidiuretic hormone (ADH) levels are inappropriately 
elevated in these patients that is inappropriate for the level of plasma osmolarity 
25,26
. In normal individuals ADH release is primarily controlled by plasma 
osmolarity. An increase in the plasma osmolarity stimulates ADH release 
resulting in water retention and restoration of plasma osmolarity to normalcy. 
The proposed mechanisms for the elevated ADH are stimulation of ADH 
release by angiotensin II, stimulation of baroreceptors in edematous patients 
with low circulating blood volume
28, 29
. 
 
As in patients with congestive heart failure COPD patients also have 
elevated levels of atrial natriuretic peptide (ANP) 
27
. In normal subjects elevated 
ANP causes prompt natriuresis and suppression of plasma renin angiotensin 
system (PRA). It is not clear why the elevated ANP is not able to cause 
natriuresis in COPD patients. It is proposed that the stimulatory effect of 
reduced renal plasma flow on PRA system probably overwhelms the inhibitory 
effect of elevated ANP levels on the PRA system 
30, 31, 32, 33
. 
 
The onset of edema is proven to be a poor prognostic marker. These 
patients have a 4 year mortality of 73% as compared to 53% for the whole 
group 
13
.With the understanding of the mechanisms underlying sodium and 
water retention in COPD it is clear that the therapeutic intervention required to 
control the edema in COPD is quite different from that used in congestive heart 
failure. The optimal therapeutic strategy should be the reversal of hypoxemia 
and improvement of the lung mechanics by reducing bronchial secretion and 
promoting maximal bronchodilation. 
 
  The role of non-invasive mechanical ventilation in reducing hypercarbia 
has not been investigated. Hyponatremia should be treated with water 
restriction. The use of ACE inhibitors is a subject of debate. Digitalis should be 
avoided unless the patient has an intrinsic cardiac disease with a documented 
low cardiac output since this drug can increase the risk of arrhythmias in the 
presence of hypoxemia. Diuretics should probably be used with caution since it 
can cause hypochloremic metabolic alkalosis which can precipitate respiratory 
depression, worsening of the blood gas tension and further worsening of the 
edema by the mechanisms discussed above. 
    
ASSOCIATION OF CHRONIC RENAL FAILURE WITH COPD 
Chronic renal failure (CRF) increases in prevalence with age
34
. In elderly 
who constitute the majority of the population affected by chronic diseases the 
muscle mass is frequently decreased. In these elderly patients serum creatinine 
which is routinely used in clinical practice as a marker of renal function can be 
within normal limits despite severe reduction in the renal function assessed by 
the glomerular filtration rate. This is called as concealed or unrecognized 
CRF
39
. 
Chronic renal failure is associated with several chronic diseases such as 
congestive heart failure and diabetes 
35, 36
. The association of chronic renal 
failure with chronic diseases has therapeutic implications and it frequently 
implies a poor prognosis 
37, 38
. The association of COPD with CRF has been 
investigated in a few studies which show that COPD is significantly associated 
with CRF. COPD is commonly associated with coronary artery disease (CAD) 
which can be associated with renal vascular disease 
40, 41
. Nicotine and selected 
heavy metals found in cigarette smoke are known to cause renal disease 
42
 
MATERIALS AND METHODS 
 
AIMS AND OBJECTIVES 
1. To compare the incidence of renal failure and hyponatremia among 
patients admitted with Chronic Obstructive Pulmonary Disease (COPD) 
and age matched control population. 
2. To determine whether the incidence of renal failure and hyponatremia is 
more among COPD patients when compared with age matched control 
population. 
PLACE OF STUDY: 
Department of General Medicine, Government Stanley Medical College 
and Hospital. 
DURATION OF STUDY: 
May 2012 – October 2012. 
INCLUSION CRITERIA: 
Patients who are previously diagnosed to have COPD based on clinical 
features and spirometry in the department of thoracic medicine who get 
admitted in medicine wards will be included in the study.  
 
EXCLUSION CRITERIA: 
Patients with COPD who have other comorbid illness which are likely to 
cause renal failure are excluded. 
These comorbid illness include 
 Diabetes. 
 Hypertension. 
 Known renal disease such as renal stones, polycystic kidney disease etc. 
 Coronary artery disease. 
 Cardiac failure. 
 Cirrhosis. 
 Ingestion of nephrotoxic drugs. 
SELECTION OF CONTROL POPULATION 
Control population included age  and sex matched persons without COPD 
and other illness known to affect renal function which are listed above.For each 
COPD patient one control patient was selected.   
 METHODOLOGY: 
COPD patients who fulfilled the study criteria were included. A total of 
56 patients were included. They were subjected to detailed history taking, 
clinical examination and investigations which included  
 Chest x ray P A view. 
 Sputum examination. 
 Blood urea. 
 Serum creatinine. 
 Serum electrolytes. 
 Complete blood count. 
 Liver function tests. 
 Urine analysis. 
For each COPD patient one age and sex matched control was selected.the 
control group of patients were also subjected to similar investigations. 
 
 
 
The creatinine clearance was estimated using the four variable MDRD 
formula. A creatinine clearance of <60 is defined as renal failure. This  cutoff 
was based on the National Kidney Foundation’s Kidney Diseases Outcome 
Quality Initiative Guidelines
43
 which marks the threshold for moderate renal 
dysfunction. 
 Serum sodium  < 135 mEq/L is defined as hyponatremia. 
 Serum albumin  < 3.5 g/dL is defined as hypoalbuminemia. 
 Hemoglobin < 13 g/ dL is defined as anemia in males. 
 Hemoglobin <12 g/dL is defined as anemia in females.     
The results were tabulated and analysed. 
The incidence of renal failure, hyponatremia, anemia and 
hypoalbuminemia were compared among the COPD patients and the control 
group and analysed using SPSS2 software for statistical significance to 
determine whether these abnormalities are more prevalent among COPD 
patients when compared with control population. 
 
 
 
RESULTS AND DISCUSSION 
  
Group 
Total 
Case Control 
N % N % N % 
SEX 
Male 46 82.1 46 82.1 92 82.1 
Female 10 17.9 10 17.9 20 17.9 
Total 56 100.0 56 100.0 112 100.0 
TABLE 5: SEX DISTRIBUTION OF PATIENTS IN THE CASES 
AND CONTROL GROUPS 
Total number of COPD patients included in the study: 56. 
Number of males: 46. 
Number of females: 10. 
Total no. of control population: 56. 
No. of males: 46. 
No. of females: 10. 
The sex distribution among the cases and controls were similar to ensure 
comparability. 
 
 
Group 
Total 
Case Control 
N % N % N % 
Age 
group 
(years) 
41 – 50 9 16.1 9 16.1 18 16.1 
51 – 60 22 39.3 22 39.3 44 39.3 
61 – 70 22 39.3 22 39.3 44 39.3 
71 – 80 3 5.4 3 5.4 6 5.4 
Total 56 100.0 56 100.0 112 100.0 
TABLE 6: AGE DISTRIBUTION AMONG THE CASES AND 
CONTROLS 
 
The age distribution among the cases and controls were similar. The 
majority of the patients were in the 51 - 70 year age group contributing to nearly 
80% of the study population. 
 
 
 
 
 GRAPH 1: AGE DISTRIBUTION AMONG CASES AND 
CONTROL 
 
Variables Group N Mean Std. Dev P-Value 
Hb 
Case 56 12.07 3.06 0.058 
Control 56 13.01 2.00  
TABLE 7: COMPARISON OF HEMGLOBIN VALUES IN CASES 
AND CONTROLS 
The mean Hb among cases was 12.07 g/dL vs 13.01g/dL among the control. 
This difference was not statistically significant with a p value of 0.058. 
 
41 - 50
16%
51 - 60
39%
61 - 70
39%
71 - 80
6%
Age group (years)
Variables Group N Mean Std. Dev P-Value 
ALBUMIN 
Case 56 4.00 0.56 
0.375 
Control 56 4.09 0.57 
TABLE 8: COMPARISON OF ALBUMIN VALUES IN CASES 
AND CONTROLS 
The mean albumin level among cases was 4 g/dL vs 4.09 g/dL among the 
control population. This difference was not statistically significant with a p 
value of 0.375. 
 
Variables Group N Mean Std. Dev P-Value 
CREATININE 
Case 56 1.15 0.43 
0.001 
Control 56 0.91 0.34 
TABLE 9: COMPARISON OF CREATININE VALUES IN CASES 
AND CONTROLS 
The mean creatinine among the cases was 1.15 mg/dL vs 0.91 mg/dL 
among the control group. This difference was statistically significant with a p 
value of 0.001. 
 
Variables Group N Mean Std. Dev P-Value 
CREATININE 
CLEARANCE 
Case 56 76.56 30.15 
<0.001 
Control 56 98.36 33.61 
TABLE 10: COMPARISON OF CREATININE CLEARANCE 
VALUES IN CASES AND CONTROLS 
The creatinine clearance was 76.56 ml/min/1.73 sq m among the cases.it 
was 98.36 ml/min/1.73 sq m among the control group. This difference was 
statistically significant with a p value of < 0.001. 
 
Variables Group N Mean Std. Dev P-Value 
SODIUM 
Case 56 131.78 7.37 
<0.001 
Control 56 139.20 3.71 
TABLE 11: COMPARISON OF SODIUM VALUES IN CASES 
AND CONTROLS 
The mean serum sodium among the cases was 131.78 m Eq/L vs 139.20 
mEq/L among the control group. This difference was statistically significant 
with a p value of <0.001. 
 
 
 
Variables Group N Mean Std. Dev P-Value 
POTASSIUM 
Case 56 3.80 0.58 
0.001 
Control 56 4.16 0.57 
TABLE 12: COMPARISON OF POTASSIUM VALUES IN CASES 
AND CONTROLS 
The mean serum potassium among the cases was 3.80 mEq/L vs 4.16 
mEq/L among the control. This difference was statistically significant with a p 
value of 0.001. 
 
 
 
 
 
 
RENAL FAILURE AMONG CASES AND CONTROLS: 
 
Group 
Total 
P-Value Case Control 
N % N % N % 
Creatinine < 60 24 42.6 9 16.1 33 28.8 0.003 
Clearance ≥ 60 32 57.4 47 83.9 79 71.2 
Total 56 100.0 56 100.0 112 100.0  
TABLE 13: RENAL FAILURE AMONG CASES AND CONTROLS 
Creatinine clearance < 60 was defined as the cut off value for renal 
failure. Among the cases 24 of 56 i.e., 42.6% had creatinine clearance <60. 
Among the control group only 9 of the 56 i.e., 16.1% had creatinine clearance < 
60.  
Thus renal failure was more prevalent among the COPD patients than 
controls. This association was statistically significant with a p value of 0.003. 
 
 
HYPONATREMIA AMONG CASES AND CONTROL 
 
 
Group 
Total 
P-Value Case Control 
N % N % N % 
Sodium 
(Hyponatremia) 
< 135 35 62.5 7 9.3 42 36.4 
0.001 
≥ 135 21 37.5 49 90.7 70 63.6 
Total 56 100.0 56 100.0 112 100.0  
TABLE 14: HYPONATREMIA AMONG CASES AND CONTROLS 
Serum sodium <135 m Eq/L is defined as hyponatremia. Among cases 35 
out of 56 i.e. 62.5% had hyponatremia. Among controls, 7 of 56 i.e. 9.3% had 
hyponatremia. 
Hyponatremia was more prevalent among COPD patients than the control 
group. This difference was statistically significant with a p value of 0.001. 
 
 
 
 
HYPOALBUMINEMIA AMONG CASES AND CONTROLS: 
 
Group 
Total 
P-Value Case Control 
N % N % N % 
Albumin level 
< 3.5 12 21.4 6 10.7 18 16.1 
0.123 
≥ 3.5 44 78.6 50 89.3 94 83.9 
Total 56 100.0 56 100.0 112 100.0  
TABLE 15: HYPOALBUMINEMIA AMONG CASES AND CONTROLS 
Serum albumin < 3.5 g/dL is defined as hypoalbuminemia. 
Hypoalbuminemia was compared in the study as this might reflect malnutrition 
and muscle wasting which can contribute to low serum creatinine despite 
significant decline in renal function. Hypoalbuminemia was present in 12 out of 
56 i.e. 21.4% among cases. It was present in 6 of 56 patients i.e. 10.7% in the 
control group. 
Though hypoalbuminemia was more prevalent among the COPD patients 
than the control population the difference was not statistically significant i.e. p 
value of 0.123.  
 
PREVALENCE OF ANEMIA AMONG THE CASES AND CONTROL 
 
Group 
Total 
P-Value Case Control 
N % N % N % 
Hb level 
Low 21 37.5 13 23.2 34 30.4 
0.100 
High 35 62.5 43 76.8 78 69.6 
Total 56 100.0 56 100.0 112 100.0  
TABLE 16: PREVALENCE OF ANEMIA AMONG THE CASES AND 
CONTROL 
Hb < 13 g/dL is defined as anemia in males. Hb < 12 g/dL is defined as 
anemia in females. Anemia was compared among the cases and controls as it 
might correlate with declining renal function. Anemia was present in 21 of 56 
patients ie 37.5% among cases. Anemia was present in 13 of 56 patients ie 
23.2% among control group. Though anemia was more prevalent among the 
cases when compared with the control population the difference was not 
statistically significant with a p value of 0.100. 
 
CORRELATION OF RENAL FAILURE WITH HYPONATREMIA  
 
 
 SODIUM 
CREATININE 
CLEARANCE 
Correlation 0.367 
P-Value 0.005 
N 56 
TABLE 17: CORRELATION OF RENAL FAILURE WITH 
HYPONATREMIA 
 
 GRAPH 2: SCATTER DIAGRAM DEPICTING THE CORRELATION 
BETWEEN SERUM SODIUM AND CREATININE CLEARANCE 
Renal failure and hyponatremia were more prevalent among COPD 
patients than controls with a statistically significant difference. 
In order to find whether there was a correlation between declining renal 
function and the degree of hyponatremia a scatter diagram was plotted with 
serum sodium along X axis and creatinine clearance along Y axis.As the 
creatinine clearance decreased there was a decline in serum sodium levels. In 
other words with worsening renal failure degree of hyponatremia also 
worsened. 
This positive correlation of creatinine clearance and serum sodium was 
statistically significant with a p value of 0.005. 
  
 
 
 
 
 
 
 
 
 
RENAL FAILURE AMONG COPD PATIENTS: 
 
 
Creatinine Clearance 
Total 
P-Value < 60 ≥ 60 
N % N % N % 
SEX 
Male 18 39.1 28 60.9 46 100.0 
0.198 
Female 6 60.0 4 40.0 10 100.0 
Total 24 42.6 32 57.4 56 100.0  
TABLE 18: RENAL FAILURE AMONG COPD PATIENTS 
 
 
 
 GRAPH 3: RENAL FAILURE AMONG COPD PATIENTS – SEX 
DISTRIBUTION 
 Total no. of COPD patients - 56. 
 No. of males - 46. 
 No. of females - 10. 
 No. of patients with renal failure - 24. 
 No. of males with renal failure - 18. 
 No. of females with renal failure - 6. 
 18 of 46 male COPD patients i.e. 39.1% had renal failure. 
 6 of 10 female COPD patients i.e. 60% had renal failure.  
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The reasons for the high prevalence of renal failure among females as 
compared with males are not known. This could probably be related to more 
severe disease which was present in these patients. 
RENAL FAILURE AMONG COPD PATIENTS - AGE WISE 
DISTRIBUTION: 
 
Creatinine Clearance 
Total 
P-Value < 60 ≥ 60 
N % N % N % 
Age 
group 
(years) 
41 - 50 5 55.6 4 44.4 9 100.0 
0.558 
51 - 60 8 33.3 14 66.7 22 100.0 
61 - 70 9 40.9 13 59.1 22 100.0 
71 - 80 2 66.7 1 33.3 3 100.0 
Total 24 42.6 32 57.4 56 100.0  
TABLE 19: RENAL FAILURE AMONG COPD PATIENTS - AGE WISE 
DISTRIBUTION 
 
RENAL FAILURE AMONG COPD PATIENTS - AGEWISE 
DISTRIBUTION 
 
GRAPH 4: RENAL FAILURE AMONG COPD PATIENTS – AGEWISE 
DISTRIBUTION 
 
 
 
 
 
HYPONATREMIA AMONG COPD PATIENTS – SEX DISTRIBUTION: 
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RENAL FAILURE
NORMAL
 Sodium (Hyponatremia) 
Total 
P-Value < 135 ≥ 135 
N % N % N % 
SEX 
Male 30 65.2 16 34.8 46 100.0 
0.476 
Female 5 50.0 5 50.0 10 100.0 
Total 35 62.5 21 37.5 56 100.0  
TABLE 20: HYPONATREMIA AMONG COPD PATIENTS – SEX 
DISTRIBUTION 
 
GRAPH 5: HYPONATREMIA AMONG COPD PATIENTS 
Total no of  COPD patients - 56. 
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Hyponatremia among COPD patients
 HYPONATREMIA 
 NORMAL 
No. of patients with hyponatremia - 35.  
Total no of male COPD patients - 46. 
No. of male COPD patients with hyponatremia - 30. 
Total no. of female COPD patients - 10. 
No. of female COPD patients with hyponatremia - 5. 
HYPONATREMIA AMONG COPD PATIENTS – AGEWISE 
DISTRIBUTION: 
 
Sodium (Hyponatremia) 
Total 
P-Value < 135 ≥ 135 
N % N % N % 
Age 
group 
41 - 50 6 66.7 3 33.3 9 100.0 
0.864 
51 - 60 12 54.5 10 45.5 22 100.0 
61 - 70 15 68.2 7 31.8 22 100.0 
71 - 80 2 66.7 1 33.3 3 100.0 
Total 35 62.5 21 37.5 56 100.0  
TABLE 21: HYPONATREMIA AMONG COPD PATIENTS – AGEWISE 
DISTRIBUTION 
 GRAPH 6: AGEWISE DISTRIBUTION OF HYPONATREMIA AMONG 
COPD PATIENTS 
 
 
 
 
The incidence of renal failure among COPD patients was 42.6% as 
compared to 16.1% among the control population in our study. 
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Hyponatremia among COPD patients
 HYPONATREMIA 
 NORMAL 
Similar results were obtained in the study Chronic Renal Failure - a 
neglected comorbidity of COPD conducted by R A Incalzi and others 
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.In this 
study the incidence of renal failure among the COPD patients was 43% as 
compared to 23.4% among controls. 
AUTHOR 
RENAL FAILURE IN 
COPD PATIENTS 
RENAL FAILURE IN 
CONTROL GROUP 
R A Incalzi 43 % 23.4% 
Present study 42.6% 16.1% 
TABLE 22: COMPARISON OF VARIOUS STUDIES WITH 
RESPECT TO RENAL FAILURE IN COPD PATIENTS 
In a study Association between COPD and CKD conducted by Van 
Gestel and others 
45
 in a cohort of 3358 vascular surgery patients the authors 
found that the prevalence of COPD was inversely related to kidney function. 
COPD was present in 47, 38 and 32% of patients with an estimated GFR <60, 
60–89 and ≥90 mL/min/1.73 m2, respectively. COPD was independently 
associated with CKD. Besides moderate and severe COPD were associated with 
increased long-term mortality in patients with CKD compared to patients 
without COPD.  
SUMMARY 
Renal failure was more prevalent among COPD patients (42.6%) when 
compared with age and sex matched control population (16.1%).this association 
was statistically significant (p=0.003). 
Hyponatremia was more prevalent among COPD patients (62.5%) when 
compared with control group (9.3%).this association was statistically 
significant(p = 0.001). 
Anemia and hypoalbuminemia were more prevalent among the COPD 
patients when compared with controls but the association was not statistically 
significant. 
The severity of renal failure correlated with the severity of hyponatremia. 
As the renal function i.e. the creatinine clearance decreased the 
magnitude of decline in serum sodium also increased. This correlation was 
statistically significant with a p value of 0.005. 
 
 
CONCLUSION 
 
COPD is the seventh most common chronic disease and is expected to 
rank fourth by the year 2020.It is the fourth most common cause of death in the 
world. It is estimated that every year half a million people die due to COPD in 
our country. The mortality due to COPD is expected to increase in the future. 
COPD is associated with several other comorbid illnesses like coronary 
artery disease, musculoskeletal diseases, malignancy because of the common 
risk factors involved. The association of COPD with renal failure was only 
recently recognized. The extent of association of COPD with renal failure has 
been analysed in a few studies in the western population. 
The reason for not recognizing the association of renal failure with COPD 
could be due to the reduced muscle mass in COPD patients leading to a normal 
serum creatinine despite significant decline in renal function. This is termed as 
concealed renal failure. This implies that whenever possible in COPD patients 
the GFR should be estimated by calculating the estimated creatinine clearance 
using standard formulas like the MDRD formula which have been validated in 
large scale studies. Serum creatinine alone would not be an ideal marker of 
renal function in these patients. 
We excluded COPD patients with other comorbid illness which might 
affect renal function. In our study we found that a significant proportion of 
patients with COPD had renal failure when compared with age and sex matched 
control population. This has therapeutic implications such as modifying the 
drug dosage to prevent toxicity. It is proposed that COPD induces systemic 
inflammation and endothelial dysfunction which could be the cause for 
increased cardiovascular mortality and renal disease. 
 
  
 
 
 
Hyponatremia was demonstrated in a significant proportion of COPD 
patients as compared with the control population. In many diseases such as 
decompensated chronic liver diseases, congestive heart failure etc. 
hyponatremia has been found to be a significant predictor of prognosis 
indicating the severity of underlying disease. In our study we found that serum 
sodium had a positive correlation with creatinine clearance i.e. with decreasing 
levels of creatinine clearance there was more severe hyponatremia. Thus 
hyponatremia, renal failure and its magnitude can be an important prognostic 
tool in patients with COPD as well. This hypothesis has to be tested in future 
studies. 
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PROFORMA 
• NAME :          SL. NO: 
• AGE /SEX:  
• ADDRESS WITH CONTACT NUMBER:  
• IP NO:  
• DATE OF ADMISSION:  
• DATE OF DISCHARGE:  
HISTORY OF PRESENTING ILLNESS:  
COUGH WITH EXPECTORATION 
SPUTUM  
CHARACTER 
QUANTITY 
BREATHLESSNESS 
FEVER 
LEG SWELLING 
DECREASED URINE OUTPUT 
 
PAST HISTORY:  
WHETHER A KNOWN CASE OF DM/HYPERTENSION/ASTHMA/TB/EPILEPSY/CARDIAC ILLNESS/ RENAL 
DISORDER  
H/O SIMILAR EPISODES IN THE PAST, IF ANY: 
H/O MAJOR ILLNESS/ HOSPITAL ADMISSIONS, IF ANY 
 
PERSONAL HISTORY: 
SMOKING HISTORY: 
NO. OF PACKS / DAY: 
NO. OF YEARS: 
ALCOHOL CONSUMPTION 
TREATMENT HISTORY: 
 
 
 
CLINICAL EXAMINATION:  
GENERAL EXAMINATION: 
SYSTEMIC EXAMINATION: 
CVS 
RS 
PER ABDOMEN 
CNS 
CLINICAL DIAGNOSIS: 
 
INVESTIGATIONS:  
• XRAY CHEST 
• SPUTUM – FOR SMEAR EXAMINATION ( GRAM STAIN, AFB STAIN,SMEAR FOR FUNGUS) 
• SPUTUM FOR CULTURE AND ANTIBIOTIC SENSITIVITY 
• ABG ANALYSIS (WHEN INDICATED), 
• RFT WITH ELECTROLYTES 
• BASIC INVESTIGATIONS(CBC, LFT, URINE ROUTINE, ECG) 
• USG ABDOMEN 
• ECHOCARDIOGRAM 
• OTHER INVESTIGATIONS(TAILORED FOR EACH PATIENT): 
 
FOLLOW UP: 
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